Background: While insulin pumps remain the most common form of therapy for youths with type 1 diabetes (T1DM), they differ in the extent to which they utilize data from continuous glucose monitoring (CGM) and automate insulin delivery. Methods: The aim of the study was to compare metabolic control in patients using different models of insulin pumps. This retrospective single-center study randomly sampled 30 patients for each of the following treatments: Medtronic 720G without PLGS (predictive low glucose suspend), Medtronic 640G or 740G with PLGS and Medtronic 780G. In the whole study group, we used CGM systems to assess patients’ metabolic control, and we collected lipid profiles. In three groups of patients, we utilized CGM sensors (Guardian 3, Guardian 4, Libre 2 and Dexcom G6) to measure the following glycemic variability proxy values: time in range (TIR), time below 70 mg/dL (TBR), time above 180 mg/dL (TAR), coefficient of variation (CV) and mean sensor glucose. Results: Medtronic 640G or 740G and 780G users were more likely to achieve a target time in the target range 70–180 mg/dL (≥80%) [Medtronic 720G = 4 users (13.3%) vs. Medtronic 640G/740G = 10 users (33.3%) vs. Medtronic 780G = 13 users (43.3%); p = 0.0357)] or low glucose variability [Medtronic 720G = 9 users (30%) vs. Medtronic 640G/740G = 18 users (60%) vs. Medtronic 780G = 19 users (63.3%); p = 0.0175)]. Conclusions: Any integration between the insulin pump and CGM was associated with better glycemic control. More advanced technologies and artificial intelligence in diabetes help patients maintain better glycemia by eliminating various factors affecting postprandial glycemia.

Continuous glucose monitoring (CGM) interpretation in people without diabetes is expanding beyond general glycemic control toward more dynamic metrics, such as Rate of Change (RoC). In this fixed-sequence pilot study conducted in 30 healthy adult females, we evaluated associations between two structured 14-day lifestyle interventions and free-living conditions using standard CGM-derived glycemic variability metrics and a novel framework based on the rate-of-change (RoC) metrics and data clarity using an unblinded Abbott FreeStyle Libre 2 monitoring. The dietary intervention (calorie-tailored low-glycemic index regular meals) were associated with lower time spent in rising (+1 to +2 mg/dL/min) and falling (−2 to −1 mg/dL/min) RoC bins by 4.76 ± 1.87% (complete-case delta, p ≤ 0.0071), whereas the 14-day physical activity intervention showed smaller and less consistent RoC changes (0.41 ± 2.20, p ≥ 0.3549). These findings, despite some major study design limitations, suggest that RoC may be more responsive and sensitive to short-term dietary pattern modifications in normoglycemic women.

Background: The grant program of Diabetes Poland (PTD) is a key funding source for diabetes-focused researchers in Poland. To assess the impact of PTD grant program on scientific productivity and career development. Methods: Bibliometric, career and financial data was extracted from PTD, Scopus and Polish science databases (RAD-on) for the 2010-2026 period. Network analysis was performed to evaluate collaboration patterns. Findings: A total of 1.8 million USD was distributed through 83 grants to 71 researchers. The annual funding increased by 9.6%/year (95%CI: 4.1 to 15.3%). Median research productivity increased from 0.6 to 1.6 publications/year (+1.0; p<0.0001). A significant increase in collaboration among awardees was observed (p<0.0001). The awardees had a significantly shorter time to associate professorship than the national average (8 vs 11.8 years; p=0.0045). Interpretation: The PTD grant program increases scientific productivity, accelerates post-doctoral advancement, and enhances integration of the Polish diabetology research community.

Introduction: Advanced hybrid closed loop (AHCL) insulin delivery systems offer considerable benefits to individuals with type 1 diabetes (T1D) in terms of glucose control and quality of life. With increasing numbers of regular users, real-life long-term data on long-term AHCL effectiveness become available.Material and methods: This was a single-centre retrospective study. We included children and young adults (age 5–25 years ) with established T1D (≥ 3 m) who started MiniMed780G therapy between January 2021 and April 2022. We excluded those naïve to continuous glucose monitoring (CGM) or insulin pumps, as well as those without good-quality baseline CGM data. Included patients were followed for 12 months, with CGM and pump data retrieved from 14-day periods before transition and 3, 6, 9, and 12 months following the start of automode. Clinical data (body weight, height, glycated haemoglobin concentration) were recorded from the most recent outpatient visits.Results: Among 81 patients who started AHCL therapy, 46 met the criteria for analysis (mean age 11.5 ±4.4 years, diabetes duration 4.4 ±3.6 years, mean glycated haemoglobin 7.0 ±1.0%). Over the year following transition, we noted a significant improvement in time in target range 70–180 mg/dl (TIR, baseline: 69.1 ±12.0% to 12 m: 76.9 ±8.5%, p < 0.0001) and time in tight range 70–140 mg/dl (baseline: 45.3 ±14.2% to 12 m: 53.3 ±10.4%, p < 0.0001). Time below target range 70 mg/dl (TBR70 mg/dl) decreased significantly for 24-hour records (p = 0.0020). Importantly, those improvements were not accompanied by an increase in daily dose of insulin or body mass index.Conclusions: A prolonged 12-month-long observation in a routine care setting demonstrates that for young CGM- and pump users with T1D, switch AHCL offers sustained benefits in glucose variability.